



INNOVATION WORKS™

Technology from the European Molecular Biology Laboratory

Atat1 – A new target for the development of novel analgesics

EMBLEM Ref. 2016-014

Challenge

- neuropathic pain afflicts millions of people worldwide
- the condition reduces the patients' overall health-related quality of life
- only 40-60% of the patients experience relief after pharmacological therapy
- there is an unmet need for novel analgesics to treat neuropathic pain

Commercial Opportunity

- collaboration opportunities
- licensing opportunities

Technology

- Atat1 is a tubulin acetyltransferase
 - knockout mice that lack the tubulin acetylation are not able to perceive mechanical pain
 - however, proprioception and the response to thermal pain remain unaffected
 - the absence of mechanical pain in the knockout lines is related to a reduced mechanotransduction caused by stiffer neuronal membranes due to the lack of tubulin acetylation
- Atat 1 is a new target for the development of analgesics

Contact


Dr. Jürgen Bauer, bauer@embl-em.de

Key Inventors

Paul Heppenstall, EMBL Monterotondo

Intellectual Property

EP priority application submitted January 2016



EMBLEM
TECHNOLOGY TRANSFER